

ABSTRACT

METHOD FOR TREATING SJOGREN'S SYNDROME USING TACI-FC FUSION PROTEIN

Provided are a drug for treating Sjogren's syndrome using a TACI-Fc fusion protein, and a dosage regimen, a dosing interval and an administration mode thereof. The results show that the provided TACI-Fc fusion protein significantly improves the ESDAI score and the MF-20 score at 24 weeks in a patient with Sjogren's syndrome, and same exhibits good security during treatment.

(FIG. 1)